Novel Noninvasive Techniques to Study Neutrophil Airway Inflammation in an Ozone Challenge Model
Primary Purpose
Healthy Subjects
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
ozoneexposure
Sponsored by
About this trial
This is an interventional basic science trial for Healthy Subjects
Eligibility Criteria
Inclusion Criteria:
- Able and willing to give written informed consent
- Healthy male and female nonsmokers, aged 18 to 55 years, with a history of less than 1 packyear having been nonsmokers for at least the last five years, FEV1 ≥ 80 % of predicted, FEV1/FVC ≥ 70 %
- Available to complete all study measurements
Women will be considered for inclusion if they are:
- Not pregnant, as confirmed by pregnancy test, and not nursing
- Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal, with documented proof of hysterectomy or tubal ligation, or meet clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit)
- Of childbearing potential and using a highly effective method of contraception during the entire study (vasectomised partner, sexual abstinence - the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to the study until at least 72 hours after the end of the study -, implants, injectables, combined oral contraceptives, hormonal IUDs)
- Subjects must be able to produce adequate sputum
- Subjects must be responsive to ozone in a screening challenge (250 ppb, 3h) defined by a ≥ 10 % increase in sputum neutrophils 6 h after the start of ozone exposure
Exclusion Criteria:
- Upper or lower respiratory tract infection in the last four weeks prior to screening
- Subjects with a positive skin prick test to common aeroallergens will be excluded
- Past or present disease, which as judged by the investigator, may affect the outcome of the study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, psychiatric disease, endocrine disease, infectious disease, inflammatory disease or pulmonary disease (including but not confined to asthma, tuberculosis, bronchiectasis or cystic fibrosis)
- Regular intake of any prescribed or over the counter medication. Exceptions include paracetamol for pain relief, oral contraceptive medication, hormonal replacement therapy, dietary and vitamin supplements
- Participation in another clinical trial 30 days prior to enrolment
- Administration of corticosteroids within the last 4 weeks prior to screening
- History of drug or alcohol abuse
- Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study
Sites / Locations
- Fraunhofer-Institut für Toxikologie und Experimentelle Medizin
Outcomes
Primary Outcome Measures
Change of smellprints in exhaled breath
Secondary Outcome Measures
Full Information
NCT ID
NCT00743704
First Posted
August 28, 2008
Last Updated
April 18, 2009
Sponsor
Fraunhofer-Institute of Toxicology and Experimental Medicine
1. Study Identification
Unique Protocol Identification Number
NCT00743704
Brief Title
Novel Noninvasive Techniques to Study Neutrophil Airway Inflammation in an Ozone Challenge Model
Official Title
Novel Noninvasive Techniques to Study Neutrophil Airway Inflammation in an Ozone Challenge Model
Study Type
Interventional
2. Study Status
Record Verification Date
April 2009
Overall Recruitment Status
Completed
Study Start Date
August 2008 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
April 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Fraunhofer-Institute of Toxicology and Experimental Medicine
4. Oversight
5. Study Description
Brief Summary
The primary objective of this pilot study is to establish a model of neutrophil airway inflammation for future testing of anti-inflammatory substances in an early stage of clinical development. Moreover, the suitability of an electronic nose for early detection and diagnosis of airway inflammation will be determined.
Detailed Description
Experimental ozone exposure of human subjects is known to induce transient neutrophilic airway inflammation with sputum neutrophilia and elevated concentrations of inflammatory mediators in bronchoalveolar lavage and sputum supernatants. In this study, ozone at a concentration of 250 ppb will be inhaled for three hours in an ozone challenge chamber.
In a recent study, ozone challenge has been discussed as a model for pulmonary diseases dominated by neutrophilic inflammation such as COPD, providing the possibility to test new anti-inflammatory substances in early stages of clinical development.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Subjects
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
15 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Other
Intervention Name(s)
ozoneexposure
Intervention Description
subjects will be exposed to either ozone (250 ppb) or filtered air in an ozone challenge chamber for three hours. Ventilation will be increased to 20 l/min/m2 by intermittent exercise on a bicycle ergometer.
Primary Outcome Measure Information:
Title
Change of smellprints in exhaled breath
Time Frame
at the end of ozone exposure and 6 h and 24 h after the start of challenge compared with baseline and exposure to filtered air
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Able and willing to give written informed consent
Healthy male and female nonsmokers, aged 18 to 55 years, with a history of less than 1 packyear having been nonsmokers for at least the last five years, FEV1 ≥ 80 % of predicted, FEV1/FVC ≥ 70 %
Available to complete all study measurements
Women will be considered for inclusion if they are:
Not pregnant, as confirmed by pregnancy test, and not nursing
Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal, with documented proof of hysterectomy or tubal ligation, or meet clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit)
Of childbearing potential and using a highly effective method of contraception during the entire study (vasectomised partner, sexual abstinence - the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to the study until at least 72 hours after the end of the study -, implants, injectables, combined oral contraceptives, hormonal IUDs)
Subjects must be able to produce adequate sputum
Subjects must be responsive to ozone in a screening challenge (250 ppb, 3h) defined by a ≥ 10 % increase in sputum neutrophils 6 h after the start of ozone exposure
Exclusion Criteria:
Upper or lower respiratory tract infection in the last four weeks prior to screening
Subjects with a positive skin prick test to common aeroallergens will be excluded
Past or present disease, which as judged by the investigator, may affect the outcome of the study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, psychiatric disease, endocrine disease, infectious disease, inflammatory disease or pulmonary disease (including but not confined to asthma, tuberculosis, bronchiectasis or cystic fibrosis)
Regular intake of any prescribed or over the counter medication. Exceptions include paracetamol for pain relief, oral contraceptive medication, hormonal replacement therapy, dietary and vitamin supplements
Participation in another clinical trial 30 days prior to enrolment
Administration of corticosteroids within the last 4 weeks prior to screening
History of drug or alcohol abuse
Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jens Hohlfeld, MD
Organizational Affiliation
Fraunhofer ITEM
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin
City
Hannover
State/Province
Niedersachsen
ZIP/Postal Code
30625
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
21439804
Citation
Biller H, Holz O, Windt H, Koch W, Muller M, Jorres RA, Krug N, Hohlfeld JM. Breath profiles by electronic nose correlate with systemic markers but not ozone response. Respir Med. 2011 Sep;105(9):1352-63. doi: 10.1016/j.rmed.2011.03.002. Epub 2011 Mar 24.
Results Reference
derived
Learn more about this trial
Novel Noninvasive Techniques to Study Neutrophil Airway Inflammation in an Ozone Challenge Model
We'll reach out to this number within 24 hrs